Clinical Trial Update: Study Comparing Radiation Therapy and Chemotherapy With or Without Nimotuzumab [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating radiation therapy and chemotherapy with or without Nimotuzumab for head and neck cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Eurofarma Laboratorios S.A. | Conditions: Carcinoma, Head and Neck Cancer | Phase 3 | Status: WITHDRAWN